Picture supply: Getty Pictures
One FTSE 250 inventory I’ve been bearish on through the years is Dr Martens (LSE:DOCS). Since its IPO precisely 5 years in the past tomorrow (29 January), the bootmaker has misplaced round 85% of its worth.
But this stays a legendary model that’s on the right track to generate practically £800m in gross sales in FY26. With the inventory falling 12% to 66p yesterday, is Dr Martens a robust turnaround candidate staring us within the face?
Blended-bag quarter
The offender for yesterday’s droop was a Q3 FY26 buying and selling assertion. Within the 13 weeks to twenty-eight December, the agency reported that quarterly gross sales fell 3.1% to £251m (or 2.7% on a relentless foreign money foundation). This included a 7% drop in direct-to-consumer (DTC) income.
A key a part of CEO Ije Nwokorie’s turnaround technique has been to chop again on reductions and promotions to enhance profitability. If profitable, this might rebuild margins over time.
Within the meantime although, inflation-weary shoppers look like looking for offers. Through the interval, which lined the run-up to Christmas, wholesale income was up throughout all areas. In Europe, the Center East and Africa, DTC income fell by 12% whereas wholesale income jumped 13%.
We have now continued to enhance the standard of our income by a disciplined strategy to promotions and this represents a headwind to total income, notably in e-commerce.
Ije Nwokorie.
On a optimistic be aware, there was a return to development within the agency’s troubled Americas division, the place income rose 2%. Yr thus far (April to December), Americas development was 4.5%, which is encouraging.
Additionally, as a part of its plan for capital-light growth into new markets, the bootmaker prolonged a distribution settlement with Latin American companion Crosby to incorporate Colombia, Costa Rica, Peru and Uruguay.
For the complete 12 months ending March, Dr Martens expects income to be “broadly flat” (about £788m). That’s decrease than the £800m that analysts have been beforehand anticipating.
But pre-tax revenue development will nonetheless be “important“, in response to administration. Final 12 months, it was £34.1m on an adjusted foundation, and this 12 months’s determine must be within the £50m-£60m vary.
All in all, this quarter was positively a combined bag.
Big comeback potential?
Dr Martens clearly possesses an iconic model that’s recognized worldwide. Nonetheless, it may be harmful as an investor to imagine {that a} robust model interprets into a very good inventory market funding. For proof, have a look at Aston Martin and Nike over the previous few years.
Based mostly on present forecasts, Dr Martens inventory is buying and selling at round 18 instances FY26 earnings. The a number of might fall as little as 11 by FY28, although so much might occur between at times.
For instance, President Trump might out of the blue slap increased tariffs on Vietnam, the place most Dr Martens boots are made lately. And inflation stays problematic, maintaining stress on shoppers’ wallets.
Given these dangers, and the early stage of the corporate’s multiyear turnaround, I don’t assume the inventory is an apparent discount. I have to see proof that administration’s technique can produce a rebound in gross sales and sustainable earnings development.
Till that occurs, I nonetheless view the inventory as a little bit of a dangerous gamble. I feel there are higher turnaround candidates to think about within the FTSE 250.
